Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Rostislav Christov Raykov sold 2,431 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of C$9.66, for a total value of C$23,476.17.
Rostislav Christov Raykov also recently made the following trade(s):
- On Monday, January 6th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$8.76, for a total transaction of C$87,552.00.
- On Friday, December 20th, Rostislav Christov Raykov acquired 25,000 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average cost of C$3.87 per share, with a total value of C$96,840.00.
- On Thursday, December 5th, Rostislav Christov Raykov purchased 796 shares of Fennec Pharmaceuticals stock. The stock was acquired at an average cost of C$8.52 per share, for a total transaction of C$6,779.05.
Fennec Pharmaceuticals Stock Down 4.9 %
TSE FRX opened at C$9.02 on Friday. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$15.20. The stock has a market cap of C$246.79 million, a PE ratio of 90.20 and a beta of 0.25. The firm has a 50-day simple moving average of C$8.80 and a 200 day simple moving average of C$7.71. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02.
Analyst Ratings Changes
Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.
View Our Latest Stock Analysis on FRX
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Recommended Stories
- Five stocks we like better than Fennec Pharmaceuticals
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Growth Stocks: What They Are, What They Are Not
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Best Stocks Under $5.00
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.